Company news

Ocular Therapeutix, Inc. news in 2026

Ocular Therapeutix, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 6, 2026

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

November 2, 2026

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

October 29, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2026

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

October 1, 2026

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

September 15, 2026

Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

September 1, 2026

Ocular Therapeutix trade; Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 13, 2026

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

August 3, 2026

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026

June 17, 2026

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026

June 3, 2026

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

May 5, 2026

Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD

April 30, 2026

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

April 29, 2026

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

April 28, 2026

Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

April 27, 2026

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

April 22, 2026

Ocular Therapeutix Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

April 15, 2026

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

April 12, 2026

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

March 31, 2026

Ocular Therapeutix™ to Participate in March Investor Conferences

February 23, 2026

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

February 22, 2026

Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

February 17, 2026

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

February 13, 2026

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

February 4, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 23, 2026

Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

January 20, 2026

Calls in 2026

Decks in 2026